HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy

Tiziana Triulzi, Luca Forte, Viola Regondi, Martina Di Modica, Cristina Ghirelli, Maria Luisa Carcangiu, Lucia Sfondrini, Andrea Balsari, Elda Tagliabue

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Through whole-transcriptome profiling of HER2+ breast carcinomas (BCs), we previously showed that those sensitive to trastuzumab are addicted to this oncoprotein and are enriched in immune pathways, raising the hypothesis that HER2 itself regulates immune cell recruitment. In the present study we investigated the relationship between HER2 activity and the pro-trastuzumab tumor immune milieu. Gene expression profiling and immunohistochemistry analysis of 53 HER2+ BCs showed that trastuzumab-sensitive tumors expressed significantly higher levels of chemokines involved in immune cell recruitment, with higher infiltration of T cells and monocytes, and higher levels of PD-1 ligands than tumors that do not benefit from trastuzumab. In vitro analysis in HER2+ BC cells revealed that CCL2 production was induced by HER2 stimulation with EGF/HRG via the PI3K-NF-kB axis, and down-modulated by HER2 inhibition with trastuzumab. CCL2 expression was higher in HER2+/ER− than HER2+/ER+ BC cell lines, and degradation of ER by fulvestrant induced an enhancement in NF-κB transcriptional activity and consequent CCL2 expression. Trastuzumab efficacy relied on CCL2 levels and monocytes present in the tumor microenvironment in FVB mice bearing HER2+ mammary carcinoma cells. HER2 signals were also found to sustain the expression of PD-1 ligands in tumor cells via the MEK pathway. Overall, our results support the concept that the activated HER2 oncogene regulates recruitment and activation of tumor infiltrating immune cells and trastuzumab activity by inducing CCL2 and PD-1 ligands and that ER activity negatively controls the HER2-driven pro-trastuzumab tumor microenvironment.

Original languageEnglish
Article numbere1512942
JournalOncoImmunology
Volume8
Issue number1
DOIs
Publication statusPublished - Jan 2 2019

Fingerprint

Tumor Microenvironment
Breast Neoplasms
Gene Expression Profiling
Neoplasms
Ligands
Monocytes
Trastuzumab
NF-kappa B
Oncogene Proteins
Mitogen-Activated Protein Kinase Kinases
Phosphatidylinositol 3-Kinases
Oncogenes
Chemokines
Epidermal Growth Factor
Immunohistochemistry
T-Lymphocytes
Cell Line

Keywords

  • Breast cancer
  • CCL2
  • chemokine
  • HER2
  • immune cells
  • trastuzumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. / Triulzi, Tiziana; Forte, Luca; Regondi, Viola; Di Modica, Martina; Ghirelli, Cristina; Carcangiu, Maria Luisa; Sfondrini, Lucia; Balsari, Andrea; Tagliabue, Elda.

In: OncoImmunology, Vol. 8, No. 1, e1512942, 02.01.2019.

Research output: Contribution to journalArticle

Triulzi, Tiziana ; Forte, Luca ; Regondi, Viola ; Di Modica, Martina ; Ghirelli, Cristina ; Carcangiu, Maria Luisa ; Sfondrini, Lucia ; Balsari, Andrea ; Tagliabue, Elda. / HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. In: OncoImmunology. 2019 ; Vol. 8, No. 1.
@article{946463d1d428400486dc25aacc1786d0,
title = "HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy",
abstract = "Through whole-transcriptome profiling of HER2+ breast carcinomas (BCs), we previously showed that those sensitive to trastuzumab are addicted to this oncoprotein and are enriched in immune pathways, raising the hypothesis that HER2 itself regulates immune cell recruitment. In the present study we investigated the relationship between HER2 activity and the pro-trastuzumab tumor immune milieu. Gene expression profiling and immunohistochemistry analysis of 53 HER2+ BCs showed that trastuzumab-sensitive tumors expressed significantly higher levels of chemokines involved in immune cell recruitment, with higher infiltration of T cells and monocytes, and higher levels of PD-1 ligands than tumors that do not benefit from trastuzumab. In vitro analysis in HER2+ BC cells revealed that CCL2 production was induced by HER2 stimulation with EGF/HRG via the PI3K-NF-kB axis, and down-modulated by HER2 inhibition with trastuzumab. CCL2 expression was higher in HER2+/ER− than HER2+/ER+ BC cell lines, and degradation of ER by fulvestrant induced an enhancement in NF-κB transcriptional activity and consequent CCL2 expression. Trastuzumab efficacy relied on CCL2 levels and monocytes present in the tumor microenvironment in FVB mice bearing HER2+ mammary carcinoma cells. HER2 signals were also found to sustain the expression of PD-1 ligands in tumor cells via the MEK pathway. Overall, our results support the concept that the activated HER2 oncogene regulates recruitment and activation of tumor infiltrating immune cells and trastuzumab activity by inducing CCL2 and PD-1 ligands and that ER activity negatively controls the HER2-driven pro-trastuzumab tumor microenvironment.",
keywords = "Breast cancer, CCL2, chemokine, HER2, immune cells, trastuzumab",
author = "Tiziana Triulzi and Luca Forte and Viola Regondi and {Di Modica}, Martina and Cristina Ghirelli and Carcangiu, {Maria Luisa} and Lucia Sfondrini and Andrea Balsari and Elda Tagliabue",
year = "2019",
month = "1",
day = "2",
doi = "10.1080/2162402X.2018.1512942",
language = "English",
volume = "8",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Taylor and Francis Inc.",
number = "1",

}

TY - JOUR

T1 - HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy

AU - Triulzi, Tiziana

AU - Forte, Luca

AU - Regondi, Viola

AU - Di Modica, Martina

AU - Ghirelli, Cristina

AU - Carcangiu, Maria Luisa

AU - Sfondrini, Lucia

AU - Balsari, Andrea

AU - Tagliabue, Elda

PY - 2019/1/2

Y1 - 2019/1/2

N2 - Through whole-transcriptome profiling of HER2+ breast carcinomas (BCs), we previously showed that those sensitive to trastuzumab are addicted to this oncoprotein and are enriched in immune pathways, raising the hypothesis that HER2 itself regulates immune cell recruitment. In the present study we investigated the relationship between HER2 activity and the pro-trastuzumab tumor immune milieu. Gene expression profiling and immunohistochemistry analysis of 53 HER2+ BCs showed that trastuzumab-sensitive tumors expressed significantly higher levels of chemokines involved in immune cell recruitment, with higher infiltration of T cells and monocytes, and higher levels of PD-1 ligands than tumors that do not benefit from trastuzumab. In vitro analysis in HER2+ BC cells revealed that CCL2 production was induced by HER2 stimulation with EGF/HRG via the PI3K-NF-kB axis, and down-modulated by HER2 inhibition with trastuzumab. CCL2 expression was higher in HER2+/ER− than HER2+/ER+ BC cell lines, and degradation of ER by fulvestrant induced an enhancement in NF-κB transcriptional activity and consequent CCL2 expression. Trastuzumab efficacy relied on CCL2 levels and monocytes present in the tumor microenvironment in FVB mice bearing HER2+ mammary carcinoma cells. HER2 signals were also found to sustain the expression of PD-1 ligands in tumor cells via the MEK pathway. Overall, our results support the concept that the activated HER2 oncogene regulates recruitment and activation of tumor infiltrating immune cells and trastuzumab activity by inducing CCL2 and PD-1 ligands and that ER activity negatively controls the HER2-driven pro-trastuzumab tumor microenvironment.

AB - Through whole-transcriptome profiling of HER2+ breast carcinomas (BCs), we previously showed that those sensitive to trastuzumab are addicted to this oncoprotein and are enriched in immune pathways, raising the hypothesis that HER2 itself regulates immune cell recruitment. In the present study we investigated the relationship between HER2 activity and the pro-trastuzumab tumor immune milieu. Gene expression profiling and immunohistochemistry analysis of 53 HER2+ BCs showed that trastuzumab-sensitive tumors expressed significantly higher levels of chemokines involved in immune cell recruitment, with higher infiltration of T cells and monocytes, and higher levels of PD-1 ligands than tumors that do not benefit from trastuzumab. In vitro analysis in HER2+ BC cells revealed that CCL2 production was induced by HER2 stimulation with EGF/HRG via the PI3K-NF-kB axis, and down-modulated by HER2 inhibition with trastuzumab. CCL2 expression was higher in HER2+/ER− than HER2+/ER+ BC cell lines, and degradation of ER by fulvestrant induced an enhancement in NF-κB transcriptional activity and consequent CCL2 expression. Trastuzumab efficacy relied on CCL2 levels and monocytes present in the tumor microenvironment in FVB mice bearing HER2+ mammary carcinoma cells. HER2 signals were also found to sustain the expression of PD-1 ligands in tumor cells via the MEK pathway. Overall, our results support the concept that the activated HER2 oncogene regulates recruitment and activation of tumor infiltrating immune cells and trastuzumab activity by inducing CCL2 and PD-1 ligands and that ER activity negatively controls the HER2-driven pro-trastuzumab tumor microenvironment.

KW - Breast cancer

KW - CCL2

KW - chemokine

KW - HER2

KW - immune cells

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85053698484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053698484&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2018.1512942

DO - 10.1080/2162402X.2018.1512942

M3 - Article

AN - SCOPUS:85053698484

VL - 8

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 1

M1 - e1512942

ER -